In human pregnancy, the transport of antibodies ... has changed from fetal blood transfusion to maternal therapy with anti-D IgG. The therapy with anti-D IgG has brought major successes associated ...

Research has shed light on how a new type of antibody treatment reactivates patients' immune cells to fight ovarian cancer.

James Harrison’s legacy is at the heart of a wild story about canny science, boundless goodwill and an errant blood ...

Immunome's strong financial position supports ongoing clinical development and potential market entry for key assets. See why ...

Tonix Pharmaceuticals (TNXP) announced a collaborative research agreement under which Tonix and Makana will study Tonix’s anti-CD40L monoclonal ...

The U.S. Food and Drug Administration has approved a self-injection version of Vyvgart Hytrulo (efgartigimod alfa and ...

For one, microglia hovering around plaques—the type that express the most TREM2—reportedly become desensitized to stimulation ...

Absci gained on animal testing phaseout news, but the change has limited near-term impact on its investment case. Read why ...

Data on tau silencing gene therapy VY1706 and anti-tau antibody VY7523 will be presented at the ... AND ROBUST CNS TAU LOWERING IN TAUOPATHY MOUSE AND NON-HUMAN PRIMATE. Wencheng Liu, Ph.D., ID:419.

Phase 1 clinical trial of its investigational half-life extended anti-IL-23 monoclonal antibody, SPY003. This milestone marks our fourth on-time clinical trial initiation in nine months.

REDWOOD CITY, CA, USA I April 14, 2025 I Pheast Therapeutics, a private biotechnology company developing novel therapies to unleash the power of macrophages ...

Henlius (2696) held its 2025 Global R&D Day under the theme of "Collaborate to Create". Senior executives from Henlius gathered with leading experts, scholars, and heads of innovation from across the ...